Madrigal Pharmaceuticals, Inc.
A maker of Rezdiffra, the first FDA-approved drug for MASH, a fatty-liver disease that can lead to serious liver damage. Founded in 2011 by Dr. Rebecca Taub to develop a thyroid-hormone molecule she had rediscovered, the company took its name from the madrigal, a Renaissance choral song, as a nod to restoring harmony to the liver. Fun quirk: it's unrelated to the fictional Madrigal Electromotive from Breaking Bad.
Granted 1.8K
Granted 37.8K · Sold 40.7K
Granted 49.6K · Sold 49.6K
Granted 65.0K · Sold 12.9K
Granted 15.5K · Sold 14.2K
Granted 9.4K · Sold 7.3K
Granted 4.0K · Sold 3.3K
Granted 4.0K · Sold 1.1K
Granted 4.4K · Sold 1.9K
Granted 16.6K · Sold 16.6K
Granted 454
Granted 2.4K
Granted 454
Granted 404
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector · 2 transactions | — | 4.09M | 1.8K | — | — |
| Taub RebeccaDirector · 47 transactions | -0.8% | 1.11M | 37.8K | — | 40.7K |
| Friedman Paul ADirector · 41 transactions | +1.6% | 855.9K | 49.6K | — | 49.6K |
| Sibold William JohnPresident and CEO, Director · 6 transactions | +47.4% | 161.8K | 65.0K | — | 12.9K |
| Levy Richard SDirector · 31 transactions | +6% | 22.5K | 15.5K | — | 14.2K |
| Dier MardiEVP and CFO · 30 transactions | +23.1% | 12.8K | 9.4K | — | 7.3K |
| Huntsman CaroleChief Commercial Officer · 15 transactions | +5.9% | 12.7K | 4.0K | — | 3.3K |
| Kelley Shannon TGeneral Counsel · 4 transactions | +31.7% | 12.1K | 4.0K | — | 1.1K |
| Soergel DavidChief Medical Officer · 3 transactions | +33% | 10.0K | 4.4K | — | 1.9K |
| Bate KennethDirector · 14 transactions | +152.5% | 8.9K | 16.6K | — | 16.6K |
| Daly James MDirector · 1 transaction | +17.3% | 3.1K | 454 | — | — |
| Thakkar RitaChief Accounting Officer · 1 transaction | — | 2.4K | 2.4K | — | — |
| Fouse Jacqualyn ADirector · 1 transaction | +41.4% | 1.6K | 454 | — | — |
| Brennan Daniel J.Director · 1 transaction | +41.8% | 1.4K | 404 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -147.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.